thought leadership

Using Viruses to Target Cancer Cells

Innovation in cancer therapeutics is moving at an accelerated pace. Advancements in the development and manufacturing of biotherapeutics have paved the was for virotherapeutics for cancer therapies. One such next-generation approach is oncolytic viruses (OV).

For the majority of OV programs moving out of R&D and into clinical trials, partnering with the right CDMO that has the experience in this specialized modality is fundamental to achieving the OV program goals.

As there are not many CDMOs with the capabilities, facilities, technologies, and expertise in viral technologies, in this article we discuss some factors to take into account when partnering with a CDMO for OV programs, as well as, Emergent CDMO's OV expertise and experience in this field.



Finding the Right CDMO Partner for Tech Transfer

Regardless of where a drug candidate is in the development pipeline, performing a technology transfer (tech transfer) presents...


Streamlining Your Process Development Journey to GMP Manufacturing

Many CDMOs specialize in certain parts of the drug development lifecycle. Meanwhile, integrated turn-key offerings that support...


How CDMOs Can Support Nanoparticles for Gene Therapy, Immuno-Oncology and Vaccines

Nanoparticles have experienced increasing demand in recent years in biopharmaceutical formulations, owing to their utility for...